Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets

Dow Jones

2025/12/17

By Adriano Marchese

Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints.

The stock traded 73% lower ahead of the morning bell at $1.18.

The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study.

The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements.

The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life.

Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration.

"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study," said Singh.

The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

December 17, 2025 09:05 ET (14:05 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2592261913"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2592261913\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2592261913?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-17 22:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592261913","market":"us","top_or_hot":-1,"title":"Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Vistagen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints. \n</p>\n<p>\n  The stock traded 73% lower ahead of the morning bell at $1.18. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study. \n</p>\n<p>\n  The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements. \n</p>\n<p>\n  The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life. \n</p>\n<p>\n  Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration. \n</p>\n<p>\n  \"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study,\" said Singh. \n</p>\n<p>\n  The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 09:05 ET (14:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVistagen Therapeutics Shares Tumble in Premarket as Anxiety Drug Test Miss Targets\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2025-12-17 22:05</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Vistagen <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints. \n</p>\n<p>\n  The stock traded 73% lower ahead of the morning bell at $1.18. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study. \n</p>\n<p>\n  The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements. \n</p>\n<p>\n  The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life. \n</p>\n<p>\n  Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration. \n</p>\n<p>\n  \"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study,\" said Singh. \n</p>\n<p>\n  The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 17, 2025 09:05 ET (14:05 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2592261913","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2592261913","pubTimestamp":1765980300,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints.The stock traded 73% lower ahead of the morning bell at $1.18.The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study.The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements.The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life.Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration.\"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsisten","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药","BK4539":"次新股","VTGN":"VistaGen Therapeutics, Inc."},"translate_title":"由于焦虑药物测试未达到目标，Vistagen Therapeutics股价盘前暴跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"VTGN":0.9},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Vistagen Therapeutics Shares fell sharply in premarket trading Wednesday after it said that its phase 3 trials of its social anxiety therapy didn't meet its endpoints. \n\n\n  The stock traded 73% lower ahead of the morning bell at $1.18. \n\n\n  The clinical-stage biopharmaceutical company said Wednesday that its experimental intranasal treatment called fasedienol didn't meet either of its primary or secondary endpoints in the Palisade-3 phase 3 study. \n\n\n  The drug is intended to treat acute social anxiety disorder but didn't demonstrate statistically significant improvements. \n\n\n  The phase 3 study tested whether a single dose of fasedienol could reduce anxiety during a public speaking challenge. Participants could later continue using the drug for up to a year in daily life. \n\n\n  Chief Executive Shawn Singh said the company is reviewing the data and plans to seek feedback from the Food and Drug Administration. \n\n\n  \"We are disappointed by the unexpected results of this public speaking challenge trial, which are inconsistent with positive outcomes observed in Phase 2 and our Palisade-2 Phase 3 study,\" said Singh. \n\n\n  The company is now in cash preservation mode, implementing measures to provide it with a reserve to last into 2027, it said. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 17, 2025 09:05 ET (14:05 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}